Video

Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab

Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.

Related Videos
Thach-Giao Truong, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD